Few FTSE 100 constituents are harder to summarise in a sentence than Halma. The group owns dozens of small, specialised businesses making gas detectors, water-quality instruments, fire-safety components, ophthalmic devices and optical assemblies, and it runs them at arm's length rather than folding them into divisions. Any useful Halma stock analysis therefore has to start with the structure, because the structure is what produces the financial profile: high margins, incremental acquisitions and a dividend record stretching back nearly half a century. This article walks through how the group earns its money, what the most recent reported figures show, and where the pressure points sit.
How Halma Makes Its Money
Halma describes itself as a group of life-saving technology companies, and its own 2026 annual report groups them into three sectors: Safety, Environmental & Analysis, and Healthcare. Third-party estimates of the number of operating companies vary between roughly 40 and over 50, which is itself telling — the portfolio changes as the group buys and occasionally sells businesses.
The operating model is deliberately decentralised. Individual companies keep their own management, brands and customer relationships; divisional chief executives lead acquisitions; and the centre sets financial targets and allocates capital rather than running operations. Halma's own description is of a structure that empowers its companies with clearly defined roles and accountability, and the annual report is explicit that such a model depends on finding exceptional leaders who can be left to operate.
Commercially, the common thread is regulation and replacement. Many of the products sit in niches where a sensor, detector or instrument is required by safety or environmental rules, must be certified, and is replaced on a cycle rather than bought once. That tends to produce pricing power and recurring demand, and it is the main reason the group has historically converted revenue into operating profit at a rate most industrial engineers do not reach.
For the year ended 31 March 2026, the sector split was as follows. Environmental & Analysis was the largest at £1,037.7m of revenue, up 33.6%. Safety came next at £947.5m, up 5.0% on a reported basis and 6.5% organically, representing roughly 37% of group revenue. Healthcare contributed £598.4m, up 4.9%. Note that segment figures include a small amount of inter-segment revenue, deducted at group level.
Halma Stock Analysis: What the FY2026 Numbers Show
Halma's financial year runs to 31 March, and it reports half-year and full-year figures rather than quarters. The most recent completed period is FY2026, the year ended 31 March 2026, reported on 11 June 2026. All figures are in sterling, the group's reporting currency.
- Revenue: £2,582.3m, up 14.9% from £2,248.1m in FY2025. Organic constant-currency growth was 16.6%.
- Adjusted EBIT: £594.5m, up 22.2%, a 23.0% margin. Stripping out £9.9m of one-off revenue and £9.3m of associated one-off adjusted profit, adjusted EBIT was £585.2m at a 22.7% margin — the figure the company presented as its underlying headline.
- Adjusted profit before tax: £564.5m, up 22.9% from £459.4m.
- Statutory profit before tax: £490.7m, against £384.3m the prior year. The gap between statutory and adjusted reflects acquisition-related charges and amortisation of acquired intangibles, which is a structural feature of a serial acquirer rather than a one-year distortion.
- Adjusted earnings per share: 114.05p, up 21%.
- Return on total invested capital (ROTIC): 16.2%, up from 15.0%.
The group also recorded its 23rd consecutive year of adjusted profit growth. Two things are worth drawing out of that table. First, margin expanded even as revenue grew at mid-teens rates, which is unusual — acquisitive growth more often dilutes margin in the year of purchase. Second, the growth was not evenly spread: Environmental & Analysis did the heavy lifting at 33.6%, while Safety and Healthcare both grew around 5%. That divergence matters for how the next few periods are read.
It is also worth being clear about where the group currently is in its reporting calendar. Half-year results for the six months to 30 September 2026 are scheduled for release on 19 November 2026 and were not available at the time of writing. The most recent company statement is a trading update issued in September 2026.
Photonics, and the Customer Concentration Question
The single most consequential development in Halma's recent fundamentals sits inside Environmental & Analysis. The group's photonics operation — Avo Photonics — supplies optical assemblies, including optical switches, into data-centre infrastructure, and that business grew 52% in FY2026. It is the main reason the segment grew a third in a single year.
The flip side is concentration. Reporting on the FY2026 results noted that a single unnamed technology customer accounted for approximately 20% of group revenue, up from around 15% a year earlier, equivalent to roughly half of Environmental & Analysis revenue. For a group whose entire investment case has historically rested on diversification across dozens of unrelated niches, that is a material change in the shape of the revenue base, and it arrived quickly.
Management has guided for this to continue in the near term. The September 2026 trading update stated that the group expects further premium growth of approximately five percentage points of group organic revenue growth from photonics in FY2027, implying a photonics growth rate of approximately 30%. The same update raised full-year adjusted EBIT margin guidance to a range of 23.5% to 24.0%, up from the prior 22.7%, while maintaining guidance for low double-digit organic constant-currency revenue growth. Halma described broad-based growth across the first half despite economic, geopolitical and market uncertainty, and said order intake remained ahead of both revenue and the prior-year period.
Investors reading the group now are therefore holding two things at once: a diversified portfolio of regulated niches growing at single digits, and a fast-growing, high-margin contract business concentrated in one customer. The arithmetic of group growth currently depends heavily on the second. Shares fell around 11% on the day of the FY2026 results as the market weighed the outlook commentary against the record profit figures.
Capital Allocation, Cash and the 47-Year Dividend Record
Halma's model requires a steady supply of acquisitions, and FY2027 to date has seen that step up sharply. The September 2026 trading update reported six acquisitions completed for a record £515m on a cash- and debt-free maximum total consideration basis, alongside three disposals generating approximately £83m net of costs. That is a meaningful increase on the group's historical run rate of bolt-on deals, and it concentrates attention on the returns those businesses eventually earn. Thermo Fisher Scientific (TMO) is a much larger version of the same approach, a US-listed instruments and consumables group that has also widened its catalogue by acquisition, and whose accounts show what that strategy looks like once it has run for decades.
The balance sheet carried that spending from a conservative starting point. At 31 March 2026, net debt stood at £769.1m on an IFRS 16 basis including leases, equating to 1.16 times adjusted EBITDA. Adjusted cash conversion was 93%, ahead of the group's 90% target but down from 112% a year earlier — a figure worth tracking, since photonics growth consumes working capital in a way that the group's traditional instrument businesses do not. Central costs are expected to be approximately £60m in FY2027.
On distributions, the board proposed a final dividend of 15.11p, taking the FY2026 total to 24.74p, an increase of 7%. That marked the 47th consecutive year in which the dividend has risen by 5% or more — one of the longest unbroken records on the London market. Some coverage noted the total came in slightly below the roughly 25.9p the market had anticipated. On FY2026 adjusted earnings of 114.05p, the dividend represents a payout of a little over a fifth of adjusted earnings, leaving the large majority of profit available for acquisitions and reinvestment. That is the trade-off the dividend record encodes: consistency and growth in the distribution, but a modest starting yield.
What the Valuation Multiple Reads, and the Risks Around It
Halma's shares are quoted in pence on the London Stock Exchange. On 26 October 2026 they closed at 3,316p — that is £33.16 per share, not £3,316 — up 2.22% from the previous close of 3,244p. Market capitalisation was approximately £12.5bn, with AJ Bell showing £12.52bn. The 52-week range was roughly 3,198p to 4,902p, meaning the shares were trading near the bottom of that band and well below the highs reached earlier in the period.
On reported multiples, AJ Bell showed a price/earnings ratio of about 33. Dividing the 3,316p share price by FY2026 adjusted earnings per share of 114.05p gives roughly 29 times historical adjusted earnings. The difference between those two numbers is simply the earnings basis: statutory earnings are lower than adjusted earnings because of acquisition amortisation, so a statutory P/E reads higher. Neither figure tells you whether the price is right; what a price/earnings multiple measures is how many years of current earnings the market is paying for, and a figure near 30 implies expectations of continued compounding rather than a steady state.
The material risks are reasonably well defined. Customer concentration is the first: if the photonics customer's data-centre build-out slows, is re-sourced, or renegotiates on price, roughly a fifth of group revenue and a disproportionate share of recent growth is exposed, and the underlying portfolio grows at mid-single digits. Second, the record £515m of acquisition spend has not yet been tested through a full cycle of integration and returns; serial acquirers are judged on incremental returns on invested capital, and ROTIC of 16.2% is the number to watch against it. Third, the raised margin guidance of 23.5% to 24.0% creates a visible bar — margin at that level has to be sustained once the photonics mix effect annualises. Fourth, a decentralised model with dozens of autonomous units depends on management depth and on acquisition discipline holding when deal sizes grow.
Against those, the structural supports are the regulated, replacement-driven nature of most end markets, order intake running ahead of revenue, leverage near one times EBITDA, and cash conversion above target.
What to Watch From Here
The half-year results due on 19 November 2026, covering the six months to 30 September 2026, are the next hard data point, and there are specific things to look for in them. The first is the split between organic and acquired growth, and within organic growth, how much came from photonics versus the rest of the portfolio — the September update's framing of roughly five percentage points of premium growth gives a benchmark. The second is whether the Safety and Healthcare sectors, both growing around 5% in FY2026, have moved off that rate. The third is adjusted EBIT margin against the newly raised 23.5% to 24.0% full-year range, and whether the first-half figure is consistent with it. The fourth is cash conversion, after the step down from 112% to 93%, and net debt after £515m of deal spending.
For comparison, the prior-year first half — the six months to 30 September 2025 — delivered revenue of £1,237.4m, up 15.2%, and adjusted EBIT of £282.0m, up 26.7%, at a 22.8% margin. That is the base the November figures will be measured against. Other LSE-listed industrials running comparable buy-and-build models, such as Diploma (DPLM) and Spirax Group (SPX), offer a reference point for how the market prices this kind of compounding over time, though each has a different end-market mix.
What would change the picture most is clarity on the durability of the photonics relationship. If that revenue proves multi-year and the underlying portfolio reaccelerates, the group looks much as it always has, only larger and growing faster. If the concentration unwinds, the question becomes what the remaining business grows at and what multiple that deserves. Both paths run through the same disclosures, which is why the segment detail and the customer concentration note in the November statement matter more than the headline growth rate.

Discussion
Log in to join the discussion